192575-19-2
中文名称
PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID;
英文名称
PPADS TETRASODIUM SALT
CAS
192575-19-2
分子式
C14H10N3Na4O12PS2
分子量
599.3
MOL 文件
192575-19-2.mol
192575-19-2 结构式
基本信息
中文别名
化合物 T16564 英文别名
PPADSPPADS Tetrasodium
4'-disulfonic acid
PPADS (sodium salt)
PPADS TETRASODIUM SALT
PPADS tetrasodium salt hydrate
PPADS tetrasodium salt, anhydrous
Pyridoxalphosphate-6-azophenyl-2'
pyridoxal-phosphate-6-azophenyl-2',4'- disulfoni
PYRIDOXALPHOSPHATE-6-AZOPHENYL-2',4'-DISULPHONIC ACID 4NA
物理化学性质
储存条件−20°C
储存条件−20°C
溶解度H2O: >10 mg/mL
溶解度H2O: >10 mg/mL
形态solid
颜色red to orange
水溶解性溶于水至100mM
稳定性在水溶液中不稳定
PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID;价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-101044 | PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID; PPADS tetrasodium | 192575-19-2 | 1mg | 370元 |
| 2024/04/30 | HY-101044 | PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID; PPADS tetrasodium | 192575-19-2 | 5mg | 750元 |
| 2024/04/30 | HY-101044 | PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID; PPADS tetrasodium | 192575-19-2 | 10 mM * 1 mLin Water | 989元 |
常见问题列表
生物活性
PPADS tetrasodiuma 是一种非选择性 P2X 受体拮抗剂。PPADS tetrasodiuma 阻断重组P2X1、-2、-3、-5，IC50 范围为1～2.6 μM。PPADS-tetrasodiuma 阻断天然 P2Y2 样 (IC50~0.9 mM) 和重组 P2Y4 (IC50~15 mM) 受体。PPADS tetrasodiuma 是豚鼠气道平滑肌 Na/Ca²⁺ 交换逆模式的抑制剂。体外研究
PPADS tetrasodiuma (1-30 μM; 10-50 minutes) inhibits Na+/Ca2+ exchanger reverse mode (NCXREV) in a time- and concentration dependent manner.
PPADS tetrasodiuma is effective at other native and recombinant P2XRs. At human P2XRs sensitivity to PPADS tetrasodiuma depended on the subtype and was highest at the hP2X1, -2, -3, -5, and -7Rs with an IC50 of ∼1–3 and ∼30 μM for the hP2X4R.
体内研究
PPADS tetrasodiuma (15-60 mg/100g body weight (BW); i.p.; every 12 hours for 8 days) inhibits glomerular mesangial cells (MC) proliferation without altering proliferation of non-MC in vivo in mesangial proliferative glomerulonephritis.
| Animal Model: | Male Sprague-Dawley ratsweighing 160 to 200 g (anti-Thy1 disease mode) |
| Dosage: | 15 mg/100g BW, 30 mg/100g BW, 60 mg/100g BW |
| Administration: | i.p.; every 12 hours for 8 days (the first PPADS injection was administered 60 minutes after disease induction, and the loading dose always contained double the amount of PPADS compared to the following injections.) |
| Result: | Specifically and dose-dependently reduced early (day 3) glomerular mesangial cell proliferation without altering proliferation of non-MC. |